Fidget with TIGIT

Cancer hides in plain sight. The immune system can’t see normal cells that have gone rogue and become entangled with blood vessels to feed and divide. Here comes the cavalry. Our initial fund has invested in drugs that are finding new pathways to seek and destroy the most stubborn cancers. The market is vast and global. Drugs in our portfolio could generate more than $50 billion annually in revenues, curing some cancers and giving patients many more days. [More]